已开发出3-取代喹唑啉-2,4(1 H ,3 H )-二酮和炔烃的氧化环加成反应。该反应由 Pd(II) 催化,并在 Ag(I) 氧化剂存在下成功发生。假设这种转化是通过喹唑啉-2,4(1 H ,3 H )-二酮的 N-H 钯化进行的,然后是邻位-C-H 活化。使用该方法,以中等至良好的收率获得了一系列5,6,7,8-四芳基-1H-氮杂[3,2,1- ij ]喹唑啉-1,3(2H ) -二酮。所得三环杂环可通过碱性水解转化为1 H-苯并[ b]azepine-9-甲酰胺衍生物。进行了 DFT 计算以阐明反应机理。
Specific Inhibitors of Puromycin-Sensitive Aminopeptidase with a 3-(Halogenated Phenyl)-2,4(1H,3H)-quinazolinedione Skeleton
摘要:
Specific puromycin-sensitive aminopeptidase (PSA) inhibitors with a 3-(halogenated phenyl)-2,4(1H,3H)-quinazolinedione skeleton were prepared and their structure-activity relationships were investigated. The nature (F, Cl or Br), number and position(s) of the halogen atom(s) introduced into the 3-phenyl group were concluded to be critical determinants of the inhibitory activity.
A compound selected from those of formula (I):
1
wherein
A, B, D, X, R
1
, R
2
, m and n are as defined in the description, their diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base.
Nouveaux composés dérivés de la quinazoline, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
申请人:Les Laboratoires Servier
公开号:EP1346992A1
公开(公告)日:2003-09-24
Composés de formule (I) :
dans laquelle :
A, B, D, X, R1, R2, m et n sont tels que définis dans la description, leurs stéréoisomères ainsi que leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable.
式(I)化合物
其中:
A、B、D、X、R1、R2、m 和 n 如描述中所定义,它们的立体异构体及其与药学上可接受的酸或碱的加成盐。